Over the counter painkillers linked to heart problems

 

pillsPainkillers such as Ibruprofen, which is commonly used to reduce pain caused by inflammation, have been linked to increased risk of heart disease.

NSAIDs (Non-steroidal anti-inflammatory drugs) are recommended to patients suffering from Osteoarthritis and other painful conditions associated with inflammation, but new research has now linked these to an increased risk of heart attacks and strokes.
The researchers have now warned GPs to take cardiovascular risk into account with each individual patient before recommending the use of NSAIDs.
In 2004, a new generation anti-inflammatory drug, the COX-2 inhibitor rofecoxib was withdrawn from the market after a trial found that it was linked to increased risk of cardiovascular disease. This sparked a wide debate over the safety of such anti-inflammatory drugs, especially in those patients already at increased risk of developing heart disease.
The ongoing debate led researchers in Switzerland to perform a full analysis of all trials comparing NSAIDs with non NSAIDs or placebos – a total of 31 trials and 116,429 people taking 7 different drugs.
However, the researchers found that although the number of cardiovascular events occurring during the trials were low, they do not consider this to be proof of the drugs being safe to take when already at increased risk of heart problems or stroke – which applies to many patients suffering from musculoskeletal problems.
When compared with placebo, rofecoxib and lumiracoxib were associated with more than twice the risk of heart attack, while ibubrofen was associated with more than three times the risk of stroke. Etoricoxib and diclofenac were associated with the highest risk of cardiovascular death – around four times the risk when compared with the placebo results.
Naproxen appeared the least harmful of the 7 drugs involved in the analysis.
The results of this research indicate that more research needs to be done on this issue, given the risks involved and the regular recommendation of these drugs. It is clear that alternatives to the traditional anti-imflammatory drugs need to be evaluated and promoted.
Perhaps a worrying outcome of this study is its links to aspirin – also an NSAID – which is recommended to people attempting to keep their heart healthy. A clear guide to the NSAIDs would benefit the public and enable people suffering from Osteoarthritis and joint pain to have more say in their treatment.
If you want to find out more about all the NSAIDs, please visit the NHS link below;
http://www.nhs.uk/Conditions/Anti-inflammatories-non-steroidal/Pages/Introduction.aspx

Arthritis drug banned from sale in UK and Germany

image

London: The drug Prexige (lumiracoxib), used to treat osteoarthritic pain has been suspended from sale by health regulators in the UK and Germany over liver damage fears.

Manufacturer, Novartis, is informing regulatory agencies around the world of these changes, which come after similar actions in other countries in recent months.

Novartis will also comply with a request from the Austrian health authority to suspend sales pending a final decision by the Committee for Medicinal Products for Human Use (CHMP), which reviews medicines in the European Union.

Patients taking Prexige in the UK, Germany, and Austria are advised to consult their medical practitioner.

Prexige was precribed as 100 mg once-daily treatment for osteoarthritic pain following EU approval through the Mutual Recognition Procedure (MRP) in October 2006. Itis also marketed and sold in Belgium, Cyprus, Hungary, Malta, Portugal, and Sweden.

Other EU countries may decide to independently suspend the marketing authorization or sale of Prexige ahead of a decision by the CHMP, which is expected in December.

Prexige is part of a class of drugs known as a COX-2 inhibitors and liver enzyme changes are a known side effect of these and traditional non-steroidal anti-inflammatory drugs (NSAIDs).

The ban comes The actions in Europe come after an Urgent Safety Restriction was initiated in August 2007 for the Prexige 100 mg dose. Prexige was first withdrawn in August 2007 in Australia where a number of liver side effects were reported, including two deaths, associated with the use of Prexige at doses higher than 100 mg. No deaths have been reported worldwide with the 100 mg dose.